| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4cdf984e52e386742b6ba53f2672f7d3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-462
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
1990-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcd70d31c12976cb0b6e5b250d72754b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4e0699f36ace760a49f2ec6029fd47c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60ab8d39c205b000741c251124b519b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fe270369ec0ad78b07e814680aec0f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8fd7454063ce6301e2eeaf93acca331
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_402c19d68278086d2c12c17887fcf8a5 |
| publicationDate |
1991-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0421876-A1 |
| titleOfInvention |
Use of active agents in the preparation of a drug for the treatment of lymphomes or related diseases |
| abstract |
Antibodies capable of binding to the human interleukin-2 receptor are applied to the preparation of a medicament for the treatment of lymphomas and tumors similar to tumor cells which involve the expression of the interleukin-2 receptor . |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8182812-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10703818-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9598493-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9204051-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7438907-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8961968-B2 |
| priorityDate |
1989-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |